Is Torrent Pharmaceuticals a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Torrent Pharmaceuticals Ltd is a good quality company .

Is Torrent Pharmaceuticals undervalued or overvalued?

The key valuation ratios of Torrent Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Torrent Pharmaceuticals share price return in the past 10 years?

Torrent Pharmaceuticals Ltd share price has appreciated 20% annually (CAGR) over the past ten years.

Is Torrent Pharmaceuticals a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Torrent Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Torrent Pharmaceuticals?

The latest standalone P/E ratio of Torrent Pharmaceuticals as of 21-Nov-2024 is 64.02.

What is the P/B ratio of Torrent Pharmaceuticals?

The latest standalone P/B ratio of Torrent Pharmaceuticals as of 21-Nov-2024 is 13.92.

What is the 52-week high and low of Torrent Pharmaceuticals?

The 52-week high of Torrent Pharmaceuticals is Rs. 3589.95 and the 52-week low is Rs. 2025.00.

Torrent Pharmaceuticals Ltd - Stock Valuation and Financial Performance

Name: Torrent Pharmaceuticals
Brand: Torrent Pharmaceuticals

BSE: 500420 | NSE: TORNTPHARM | Pharmaceuticals & Drugs | Large Cap

Place order

Torrent Pharma Share Price

₹3,096.25 1.45 0.05%
as on 21-Nov'24 14:02

10 Year X-Ray of Torrent Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	27%	45.6%	20.4%	13.8%	9.8%	15.3%	17.6%	14.4%	20.3%	24.3%	-
Value Creation Index ⓘ	1.0	3.1	0.8	0.2	-0.1	0.4	0.6	0.3	0.8	1.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	4,653	6,667	5,816	5,950	7,673	7,939	8,005	8,508	9,620	10,728	11,032
Sales YoY Gr.	-	43.3%	-12.8%	2.3%	29%	3.5%	0.8%	6.3%	13.1%	11.5%	-
Adj EPS ⓘ	16.6	51.8	23.1	14	19.5	28	36	28.3	36.3	46.8	53.2
YoY Gr.	-	212.1%	-55.5%	-39.1%	38.8%	43.5%	28.8%	-21.3%	28.2%	28.9%	-
BVPS (₹) ⓘ	73.6	103.2	128.5	136.6	139.6	142.5	172.5	175.9	183.1	202.6	221.7
Adj Net Profit ⓘ	562	1,753	781	475	659	946	1,219	959	1,229	1,585	1,802
Cash Flow from Ops. ⓘ	810	2,742	1,009	894	1,798	1,393	2,005	1,803	2,368	3,266	-
Debt/CF from Ops. ⓘ	3.4	0.9	2.5	7.2	3.4	4.2	2.4	2.2	2.2	1.2	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	9.7%	6.9%	10.3%	11.5%
Adj EPS ⓘ	12.2%	19.2%	9.1%	28.9%
BVPSⓘ	11.9%	7.7%	5.5%	10.6%
Share Price	20%	28.9%	30.5%	46.1%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	25.6	58.6	19.9	10.6	14.1	19.8	22.9	16.3	20.2	24.3	25.1
Op. Profit Mgn % ⓘ	21.9	41	23.7	22.5	25.8	27.3	31	28.6	29.5	31.4	32.6
Net Profit Mgn % ⓘ	12.1	26.3	13.4	8	8.6	11.9	15.2	11.3	12.8	14.8	16.3
Debt to Equity ⓘ	1.1	0.7	0.6	1.4	1.3	1.2	0.8	0.7	0.9	0.6	0.2
Working Cap Days ⓘ	238	188	216	123	105	108	117	116	107	107	94
Cash Conv. Cycle ⓘ	10	-55	-6	-58	-56	-46	-32	-15	-1	-4	10

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 25.10%

Sales growth is growing at healthy rate in last 3 years 10.25%

Debt to equity has declined versus last 3 years average to 0.57

Net Profit has been subdued in last 3 years 9.14%

Sales growth is not so good in last 4 quarters at 9.39%

Latest Financials - Torrent Pharmaceuticals Ltd.

	Standalone	Consolidated
TTM EPS (₹)	48.3	53.2
TTM Sales (₹ Cr.)	8,947	11,032
BVPS (₹.) ⓘ	222.4	221.7
Reserves (₹ Cr.) ⓘ	7,357	7,335
P/BV ⓘ	13.92	13.96
PE ⓘ	64.02	58.13

From the Market
52 Week Low / High (₹)	2025.00 / 3589.95
All Time Low / High (₹)	4.06 / 3589.95
Market Cap (₹ Cr.)	1,04,742
Equity (₹ Cr.)	169.2
Face Value (₹)	5
Industry PE ⓘ	43

Management X-Ray of Torrent Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Torrent Pharma

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Torrent Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	4,653	6,667	5,816	5,950	7,673	7,939	8,005	8,508	9,620	10,728
Operating Expenses ⓘ	3,633	3,937	4,438	4,609	5,696	5,769	5,524	6,077	6,796	7,364
Manufacturing Costs	443	446	610	576	691	672	674	735	726	716
Material Costs	1,281	1,432	1,630	1,535	2,041	1,982	1,960	2,231	2,513	2,459
Employee Cost	842	842	993	1,135	1,404	1,429	1,440	1,526	1,678	1,984
Other Costs ⓘ	1,067	1,217	1,205	1,362	1,560	1,686	1,451	1,584	1,879	2,205
Operating Profit ⓘ	1,020	2,730	1,377	1,341	1,976	2,170	2,480	2,431	2,824	3,364
Operating Profit Margin (%)	21.9%	40.9%	23.7%	22.5%	25.8%	27.3%	31.0%	28.6%	29.4%	31.4%
Other Income ⓘ	286	229	223	307	64	121	57	197	63	62
Interest ⓘ	175	184	206	308	504	451	353	255	333	354
Depreciation ⓘ	191	238	307	409	618	654	658	662	707	808
Exceptional Items ⓘ	0	-194	0	0	-357	0	0	-485	0	88
Profit Before Tax ⓘ	940	2,343	1,088	931	562	1,187	1,526	1,226	1,847	2,352
Tax ⓘ	189	610	155	253	125	162	274	449	602	696
Profit After Tax	751	1,733	934	678	436	1,025	1,252	777	1,245	1,656
PAT Margin (%)	16.1%	26.0%	16.1%	11.4%	5.7%	12.9%	15.6%	9.1%	12.9%	15.4%
Adjusted EPS (₹)	22.2	51.2	27.6	20.0	12.9	30.3	37.0	23.0	36.8	48.9
Dividend Payout Ratio (%)	25%	34%	25%	35%	66%	53%	47%	105%	60%	57%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	2,491	3,494	4,350	4,622	4,724	4,823	5,837	5,953	6,198	6,856
Share Capital ⓘ	85	85	85	85	85	85	85	85	169	169
Reserves ⓘ	2,406	3,409	4,266	4,538	4,640	4,739	5,753	5,868	6,029	6,687
Minority Interest	0	0	0	1	0	0	0	0	0	0
Debt	2,504	1,853	2,241	5,737	4,847	4,395	3,645	3,046	4,261	3,241
Long Term Debt	2,185	1,850	2,241	4,111	3,913	3,304	2,941	2,123	2,496	1,604
Short Term Debt	319	3	0	1,626	934	1,091	704	923	1,765	1,638
Trade Payables	1,828	2,260	1,749	2,048	2,097	2,049	2,067	1,674	1,679	2,089
Others Liabilities ⓘ	997	1,167	1,051	1,559	2,083	2,310	2,104	1,933	2,330	2,318
Total Liabilities ⓘ	7,820	8,775	9,392	13,967	13,751	13,577	13,653	12,606	14,468	14,505
Fixed Assets
Gross Block	3,543	3,794	4,910	9,449	9,935	10,334	10,512	10,728	12,812	13,485
Accumulated Depreciation	710	934	1,221	1,595	2,188	2,801	3,447	4,306	4,690	5,346
Net Fixed Assetsⓘ	2,833	2,859	3,688	7,855	7,748	7,533	7,065	6,423	8,121	8,138
CWIP ⓘ	678	1,042	519	647	617	712	889	630	765	361
Investmentsⓘ	298	780	804	492	353	2	181	226	199	173
Inventories	1,067	1,358	1,559	1,966	1,935	2,148	2,681	2,462	2,230	2,279
Trade Receivables	1,587	1,445	951	1,253	1,436	1,649	1,523	1,632	1,944	1,844
Cash Equivalents	567	647	894	867	816	667	604	403	571	839
Others Assetsⓘ	789	644	977	886	846	865	710	829	638	872
Total Assets ⓘ	7,820	8,775	9,392	13,967	13,751	13,577	13,653	12,606	14,468	14,505

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	810	2,742	1,009	894	1,798	1,393	2,005	1,803	2,368	3,266
PBT ⓘ	940	2,343	1,088	931	562	1,187	1,526	1,226	1,847	2,352
Adjustment ⓘ	338	552	430	607	1,418	876	993	1,350	937	994
Changes in Working Capital ⓘ	-409	424	-125	-360	99	-386	-338	-352	-18	418
Tax Paid ⓘ	-58	-577	-384	-284	-281	-284	-176	-421	-398	-498
Cash Flow From Investing Activity ⓘ	-2,162	-838	-787	-4,707	-241	199	-449	-197	-2,415	-168
Capex	-236	-592	-486	-789	-661	-403	-334	-196	-415	-299
Net Investments	16	-20	-175	38	395	585	-121	-8	-13	118
Others ⓘ	-1,942	-226	-126	-3,956	24	17	5	7	-1,987	13
Cash Flow From Financing Activityⓘ	1,212	-1,435	-193	3,417	-1,314	-1,549	-1,651	-1,781	77	-2,780
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	1,516	-65	205	2,339	238	-451	-543	-1,033	423	-1,236
Interest Paid ⓘ	-195	-212	-191	-276	-503	-485	-356	-258	-303	-371
Dividend Paid ⓘ	-200	-840	-204	-265	-310	-719	-338	-677	-863	-1,015
Others ⓘ	91	-319	-3	1,619	-740	106	-413	187	820	-157
Net Cash Flow ⓘ	-140	469	29	-395	242	42	-95	-175	30	319

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	34.19	57.92	23.8	15.12	9.34	21.47	23.49	13.18	20.5	25.38
ROCE (%)	26.98	45.63	20.36	13.81	9.75	15.28	17.62	14.35	20.32	24.28
Asset Turnover Ratio	0.73	0.81	0.64	0.96	1.05	1.09	1.09	1.16	1.21	1.15
PAT to CFO Conversion(x)	1.08	1.58	1.08	1.32	4.12	1.36	1.6	2.32	1.9	1.97
Working Capital Days
Receivable Days	105	83	75	36	34	38	39	38	40	41
Inventory Days	81	66	91	57	49	50	59	62	52	49
Payable Days	464	521	449	451	371	382	383	306	244	280

Torrent Pharmaceuticals Ltd Stock News

Torrent Pharmaceuticals Ltd FAQs

What is the share price of Torrent Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Torrent Pharma on 21-Nov-2024 14:02 is ₹3,096.3.

What is the market cap of Torrent Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 14:02 the market cap of Torrent Pharma stood at ₹1,04,742.1.

What is the P/E ratio of Torrent Pharma?

The latest P/E ratio of Torrent Pharma as of 21-Nov-2024 14:02 is 64.02.

What is the P/B ratio of Torrent Pharma?

The latest P/B ratio of Torrent Pharma as of 21-Nov-2024 14:02 is 13.92.

What is the 52-week high and low of Torrent Pharma?

The 52-week high of Torrent Pharma is ₹3,590 and the 52-week low is ₹2,025.

What is the TTM revenue of Torrent Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Torrent Pharma is ₹8,947 ( Cr.) .

About Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals, the flagship Company of Torrent Group is one of the leading pharma companies of the Country. The Company was a pioneer in initiating the concept of niche marketing in India and is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent Pharma's competitive advantage stems from the world-class manufacturing facilities, advanced R & D capabilities, extensive domestic network and a widespread global presence in many countries.

The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceutical business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with 90 year old Heumann from Pfizer to enter the German market. Later on purchased ANDA of Minocycline from Ranbaxy for the US Market in 2015. In January 2018, Torrent also acquired Bio-Pharm, Inc. (BPI) a generic pharmaceuticals and OTC Company, based in Levittown Pennsylvania, USA, which also included a US FDA registered manufacturing facility. Torrent Pharma is committed towards ‘not just healthcare but lifecare’.

Business area of the company

Torrent Pharmaceuticals has established itself as a major player in the Indian Pharma arena. The company has well segregated marketing divisions, strategically structured on specific therapeutic areas and enjoys dominance in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). With Unichem's domestic business acquisition, Torrent has entered the list of top pharma firms in the Indian Pharma Market (IPM) and is ranked No 8 in the IPM.

Manufacturing facilities

The company’s manufacturing facilities are loaced at Indrad, Dahej, Baddi, Sikkim Unit I & II, Sikkim Unit III, Vizag, Pithampur, Levittown Pennsylvania and HSE Forum.

Awards and recognition

1984-85 Received Chemexcil Export Award
1984-85 Received Udyog Ratna Award
1985-86 Received Chemexcil Export Award
1986-87 Received Chemexcil Export Award
1986-87 Received IDMA Quality Excellence Award
1986-87 Received Export Award from Govt. of Gujarat
1987-88 Received Export Award from Govt. of Gujarat
1989-90 Received Chemexcil Trishul Award for highest Pharma Exports
1989-90 Received IDMA Quality Excellence Award
1988-89 Received Chemexcil Export Award
1990-91 Received Export Award from Govt. of Gujarat
1990-91 Pride of Asia International award for excellence in Pharmaceuticals Products by international Friendship
1991-92 Received Export Award from Govt. of Gujarat
1991-92 Received National Export Award
1992-93 Received IDMA Quality Excellence Award
1999-00 GCCI Export Appreciation Award
1999-00 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility.
2000-01 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility
2001-02 Torrent Pharmaceuticals bagged the 'Best Suppliers' award by the Sri Lankan State Pharmaceutical Corporation.
2001-02 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility and Silver Trophy forits API manufacturing facility
2002-03 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award 2003 for both Formulations and API manufacturing facilities
2009-10 Baddi Plant awarded Five Star rating by British Safety Council
2012-13 Indrad Plant awarded Sword of Honor for Occupational Health & Safety by British Safety Council
2014-15 Torrent Pharma recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards 2014
2017-18 Listed amongst top five ‘Fastest Growing Companies (Middleweights Category)’ by Business World Magazine
2017-18 Executive Chairman, listed by Business World Magazine, amongst India's Most Valuable CEOs in Large Category

Accreditation

Approvals research centre

National GLP Compliance Monitoring Authority, India*
National Accreditation Board for Testing & Calibration Laboratories (NABL), India*
ISO 14001:2004 and OHSAS 18001:2007, ISOQAR Ltd., UK*
ISO 50001 : 2011, ISOQAR Ltd. UK*

(*Also applicable for Bio-Evaluation Center)

Bio-evaluation centre accreditations

The Drug Controller General (India) (DCGI)
ANVISA (BRAZIL)
Ministry of Health (UAE)

Studies inspected and approved

USFDA
AFFSAPS (ANSM)
DKMA
AGES
ANVISA

Studies accepted by Regulatory Agencies in:

Russia
CIS Countries
Australia
ASEAN countries
South Africa
African countries
South American countries

Milestones

1959: U. N. Mehta started Pharma operations.
1971: Trinity Laboratories renamed as Torrent Pharmaceuticals Limited.
1980: First manufacturing facility set up at Vatva in Ahmedabad
1983: Entry into the international markets. First Export order to USSR received
1984: Torrent Laboratories Limited received Chemexcil Export Award.
1984: Torrent Laboratories Limited received Udyog Ratna Award.
1985: Torrent Laboratories Limited received IMC Golden Jubilee Endowment Award for Export Performance.
1985: Torrent Exports Limited received Export Award From Govt. of Gujarat.
1985: Torrent Laboratories Limited received IDMA Quality Excellence Award.
1985: Torrent Laboratories Limited received Chemexcil Export Award.
1986: Torrent Laboratories Limited received Chemexcil Export Award.
1986: Torrent Laboratories Limited received IDMA Quality Excellence Award.
1986: Torrent Exports Limited received Export Award from Govt. of Gujarat.
1987: Torrent Laboratories Limited received Chemexcil Export Award.
1987: Torrent Exports Limited received Export Award from Govt. of Gujarat.
1989: Second manufacturing plant commissioned at Indrad
1989: Torrent Exports Limited received Chemexcil Trishul Award for highest Pharma Exports.
1989: Torrent Pharmaceuticals Limited received IDMA Quality Excellence Award.
1988: Torrent Laboratories Limited received Chemexcil Export Award.
1990: Torrent Exports Limited received National Export Award.
1990: Pride of Asia International award for excellence in Pharmaceuticals Products by international Friendship.
1992: Torrent Pharmaceuticals Limited received IDMA Quality Excellence Award.
1995: Torrent Gujarat Biotech Limited plant commissioned.
1996: U N Mehta bestowed with the title of Corporate Business Man of the Year
1998: Torrent Exports renamed as Torrent Ltd. as part of restructuring and consolidation exercise.
1998: State-of-the-art R&D Centre commissioned.
1998: Torrent Pharmaceuticals Limited acquires Pharma related investments and business of Torrent Exports Limited.
1999: Restructuring of Torrent Pharmaceuticals Ltd. through formation of three new divisions – Prima, Vista, Psycan.
1999: First New Chemical Entity Patented by Torrent Research Center
1999: GCCI Export Appreciation Award
1999: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility
2000: Torrent Research Centre received OECD Standards of Good Lab. Practices Certificate from Dutch Health Ministry.
2000: Indrad Plant received ISO 9001:2000 Certificate
2001: Torrent Pharma ranked in the top 10 Indian Companies in terms of Return on Capital Employed (ET - BCG Study Feb - 2001).
2001: Torrent Pharmaceuticals bagged the 'Best Suppliers' award by the Sri Lankan State Pharmaceutical Corporation
2001: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility and Silver Trophy for its API manufacturing facility
2001: Torrent do Brasil Ltda. set up in Brazil
2002: Discovered and patented AGE (Advanced Glycosylation End-products) molecule.
2002: Torrent Pharma's Indrad Plant receives ISO 14001:1996 and OHSAS 18001:1999
2002: Torrent's R&D Centre received ISO/IEC 17025:1999 for its facilities by National Accreditation 2002:
2002: Board for Testing and Calibration Laboratories (NABL).
2002: Addition of a new marketing division, MIND
2002: Dual Retard Inlay Technology, Compact Tablet Technology, Gastro Retentive System and Multiparticulate / Matrix Based SR / Modified Release Formulations developed indigenously by Torrent Research Center (2002)
2002: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award 2003 for both Formulations and API manufacturing facilities
2002: Brazilian Sanitary Surveillance Agency accredited Torrent's R&D Centre with ANVISA, authorizing it to conduct Bioequivalance Studies.
2003: Torrent Pharma Inc. set up in USA.
2003: GMP Certification received from European Union by Torrent Pharmaceuticals Manufacturing Plant
2003: Torrent Pharma Philippines Inc. set up.
2004: Torrent Pharma's manufacturing facility at Indrad received MHRA (UK) and TGA (Australia) approvals
2004: Restructuring of marketing divisions and addition of new division, Delta.
2004: Torrent Australasia Pty Ltd. incorporated in Australia
2005: New manufacturing unit at Baddi, Himachal Pradesh, set up to cater to domestic formulations market.
2005: Torrent Pharma signed an agreement with Novo Nordisk India to establish a new, dedicated formulation and packaging facility for Insulin, exclusively for Novo Nordisk.
2005: Acquired Heumann Pharma GmbH & Co Generica KG, a Pfizer group company, in Germany.
2005: Two new marketing divisions- AXON and NEURON set up to cater to neuropsychiatry segment.
2005: Entered into a research collaboration with AstraZeneca for developing novel anti-hypertensive drug.
2005: Torrent Pharma's QC department at Chhatral manufacturing plant accredited with ISO/IEC- 17025 by NABL
2006: The API and formulations manufacturing facilities located at Indrad (Gujarat, India) got US FDA approval
2006: Torrent Pharma and Pharma Dynamics (Pty) Ltd, South Africa signed a Technical Agreement for supplies of a range of products
2007: Indrad Plant certified with ISO 9001: 2000 (Quality Management System), ISO 14001:2004 (Environmental Management System) and OHSAS 180001:1999 (Occupational Health and Safety Management System) by ISOQAR, UKAS accredited body
2007: Construction of Sikkim Plant started
2008: Baddi Plant received GMP certification from Government of Upper Bavaria, Germany
2009: Commissioned dedicated formulation and packaging unit for manufacturing Insulin exclusively for Novo Nordisk
2009: Entered into license and supply agreement with AstraZeneca for marketing its products in international market
2009: Baddi Plant awarded Five Star rating by British Safety Council
2010: Baddi Plant received OHAS Audit 18001:2007certification; facility approved by the regulatory authority of Uganda
2010: An advanced facility for Stability Studies set up at Indrad Plant
2010: Entered into the therapeutic area of Gynaecology
2010: Commenced commercial operations of Laboratories Torrent S.A. de C.V., Mexico
2010: Started construction of Dahej manufacturing facility
2010: Commissioned a subsidiary in United Kingdom and Romania
2010: Torrent Research Center develops Long Acting Injectables technology
2010: Foray into oncology segment
2011: Sikkim Plant commences operation
2011: Indigenous Nasal Drug Delivery system developed by Torrent Research Center
2011: Set up Sparsh, a dedicated division to cater to Dermatology Segment
2012: Indrad Plant awarded Sword of Honor for Occupational Health & Safety by British Safety Council
2012: Topical Foams system developed by Torrent Research Center
2013: Torrent Pharma enters into a licensing agreement with Reliance Life Sciences for three biosimilars - Rituximab, Adalimumab, and Cetuximab
2014: Acquired Elder Pharma's identified Indian Branded Formulation Business in India and Nepal
2014: Launched Nephro, a dedicated division to cater to the Nephrology Segment
2014: Torrent Pharma's Dahej Plant commences operations
2015: Torrent acquires 100% stake of Zyg Pharma
2015: Torrent Pharma recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards 2014
2016: Dahej Plant receives USFDA approval
2016: Acquired API manufacturing Unit of Hyderabad based Glochem Industries Limited
2017: Acquired Unichem’s Domestic and Nepal business and also its Sikkim manufacturing facility.
2017: Listed amongst top five ‘Fastest Growing Companies (Middleweights Category)’ by Business World Magazine
2017: Executive Chairman, listed by Business World Magazine, amongst India's Most Valuable CEOs in Large Category
2017: Acquired Women Healthcare brands from Novartis
2018: Acquired US based Bio-Pharm, Inc. (BPI) which includes US FDA registered manufacturing facility. This is Torrent's first overseas manufacturing unit.
2019: Torrent & Glenmark sign licensing agreement for co-marketing of Remogliflozin Etabonate in India